China to establish pharmaceutical patent linkage and restoration under U.S./China trade deal
Registered Content

As part of the Phase One U.S./China trade agreement signed on Jan 15, 2020, China has agreed to establish pharmaceutical patent linkage and restoration, which, once implemented, would give...

Hogan Lovells Publications

The Foreign Investment Law gets wings: draft implementation regulations released for public consultation Corporate Alert

Following the ground-breaking People's Republic of China (PRC) Foreign Investment Law (FIL) which unifies and replaces the main existing rules governing foreign invested enterprises (FIEs)...


China implements new foreign exchange rules in the Free Trade Zones

Between July and August 2019, China's State Administration of Foreign Exchange ("SAFE") made one step forward towards China's comprehensive foreign exchange reform. The local branches of...

Published Works

Getting The Deal Through Automotive 2019 − China

A joint Hogan Lovells & GTDT publication on the law and regulation governing the automotive industry in China.

Hogan Lovells Publications

China updates negative list and encourages sector catalogue for foreign investments: a step in the right direction International Trade and Investment Alert

On 30 June 2019 the National Development and Reform Commission and the Ministry of Commerce jointly released the Special Administrative Measures (Negative List) for Foreign Investment...

Hogan Lovells Publications

New human genetic resources regulations in China Government Relations and Public Affairs Alert

On 28 May 2019 the People's Republic of China State Council promulgated the People's Republic of China Human Genetic Resources Administrative Regulations, which took effect on 1 July 2019.


Pharma Companies May Benefit from Proposed Patent Law Changes in China; Public Comment Invited

On January 4, China’s National People’s Congress (NPC) released draft amendments to the Chinese Patent Law, proposing expanded and enhanced protections that may provide real...


Considerations for Structuring and Bridging the Valuation Gap in Life Sciences M&A Transactions

Two of the main issues that parties to life sciences transactions must consider at the outset of a transaction are how to structure the deal and what happens when the acquiror and seller...


Preliminary Regulatory Barriers Life Sciences Acquirers Face in China/U.S. Cross-Border Transactions

When entering into an acquisition of a U.S. life sciences company, Chinese acquirers will often face a number of preliminary hurdles from regulators in both the People’s Republic of...

Loading data